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ABSTRACT 
Despite the compelling clinical need to regenerate damaged tissues/organs, the impressive 
advances in the field of tissue engineering have yet to result in viable engineered tissue 
products with wide-spread therapeutic adoption. Although bioreactor systems have been 
proposed as a key enabling factor in the manufacture of standardized and cost-effective 
engineered products, this concept appears slow to be embraced and implemented. Here we 
address scientific, regulatory and commercial challenges intrinsic to the bioreactor-based 
translation of tissue engineering models into clinical products, proposing a roadmap for the 
implementation of a new paradigm. The roadmap underlines that bioreactors must be 
implemented throughout product development, allowing the scientific, medical, industrial and 
regulatory parties to address basic research questions, conduct sound pre-clinical studies, and 
ultimately facilitating effective commercialization of engineered clinical products. 
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INTRODUCTION 
In the last couple of decades, the appealing possibility of combining living cells with suitable 
carriers for the regeneration of damaged or lost tissues and organs has promoted the 
interaction of scientists, engineers, clinicians and business people, leading to the 
establishment and progressive consolidation of the field of tissue engineering. Examples of 
successful clinical implementation of the developed concepts include restoration of corneal 
surfaces [1,2], replacement of a bronchus segment [3], reconstruction of bone [4] and 
cartilage defects [5], as well as of diseased bladder [6]. Despite significant achievements and 
enormous clinical demand, the clear need for viable tissue engineered products that are 
broadly available to patients as part of the routine toolkit of medical treatments still remains 
unsatisfied. On the one hand, this may be due to a relatively limited establishment of 
prospective, randomized clinical studies, demonstrating reproducibly superior effectiveness of 
engineered grafts as compared to conventional treatments. On the other hand, addressing 
manufacturing-related issues has been proposed to be key for the success of cell-based 
engineered products [7]. Indeed, as in other applications of biotechnology (e.g., for the 
production of antibodies or molecular vaccines), successful clinical use of engineered tissue 
products, as well as their commercial exploitation, may be critically dependent on the 
introduction of bioreactor-based manufacturing systems [8]. Bioreactors, intended as a means 
to generate and maintain a controlled physico-chemical culture environment, indeed represent 
a key element for the automated, standardized, traceable, cost-effective, safe and regulatory 
compliant manufacturing of cell-based products or engineered grafts for clinical applications 
[9,10] (Figure 1). However, notwithstanding the promise of a few pioneering systems 
currently under development or clinical testing (e.g., Octane Biotech Inc., Canada - 
http://www.octaneco.com/biotech and Aastrom Biosciences Inc., USA - 
http://www.aastrom.com) this concept has not yet broadly facilitated the transfer of cell-based 
processes into clinically and commercially viable therapeutic solutions. In this paper, we 
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address the scientific, regulatory and commercial challenges that are hampering the 
bioreactor-based translation of tissue engineering into clinical products, and based on these 
issues, propose a roadmap for the implementation of a new paradigm.  The new paradigm is 
fundamentally rooted in the perspective that sensor-based bioreactors must be deployed and 
validated throughout the product development pipeline, from initial conception until 
manufacturing of the implant. 
 
SCIENTIFIC ASPECTS 
The introduction of bioreactors in the field of tissue engineering was initially advocated as a 
powerful means to apply defined regimes of physical forces, with the ultimate goal to regulate 
and possibly improve the mechanical functionality of the resulting engineered grafts [11]. 
This approach has advanced scientific understanding of mechanoregulation of developing 
tissues and emphasized the importance of controlled physical conditioning in tissue 
regeneration. However, the effective need to apply mechanical forces in vitro to generate 
more functional grafts is still controversial. Indeed, beyond a few cases where graft 
functionality might need to be fully developed prior to implantation, such as for engineered 
blood vessels [12] or heart valves [13], it is becoming increasingly clear that tissue maturation 
could be more efficiently induced by the physiological biochemical and mechanical cues of 
our body as an ‘in vivo bioreactor’ [14], provided that an appropriate quality “starting 
material” is implanted. Moreover, introducing a mechanical loading regime that correctly 
emulates the dynamic physiology of the body in order to generate a fully functional tissue 
would likely make the manufacturing process too complicated and lengthy, and as a result, 
too expensive and impractical.  
In principle, as compared to smart functionalized materials or drug delivery devices, cell-
based grafts have the potential to provide superior clinical outcomes, due to the multivalent 
biological activity of cells (e.g., multiple growth factor release, self-contribution to tissue 
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regeneration) and/or of the deposited extracellular matrix (e.g., efficient storage and release of 
morphogens, physiologically functional mechanical properties). However, engineered 
products will only be a viable and competitive option against the upcoming off-the-shelf 
block busters in regenerative medicine [7] if they are manufactured with reproducible 
properties, a prerequisite for consistent clinical outcomes. This important target is mainly 
challenged by the intrinsic variability, often not sufficiently underlined, in the behavior of 
human cells from different batches or donors [15], as well as by the sensitivity of cells to 
perturbations in the culture environment. While the spotlight of bioreactor-based tissue 
engineering has typically been on enhancing the functionality or maturation stage of the 
resulting engineered tissues, the potential for controlled sensor-based bioreactor systems to 
minimize process and product variability should receive equal attention. By monitoring and 
controlling physico-chemical culture parameters, bioreactors can help to standardize both the 
required bioprocesses and the resulting engineered graft, and ensure the automated protocols 
are compatible with regulatory and commercialization requirements (see sections below and 
Text Box 1). Moreover, by streamlining culture processes and bypassing operator/handling-
dependent procedures, bioreactor-based systems have the potential to increase the robustness 
and stability of the graft manufacturing process [16,17]. 
Clearly, in order to broadly deliver on the described opportunities, continued progress against 
dominant challenges remains essential. These are not only related to the limited availability of 
on-line, non-invasive ‘sensing’ techniques for important culture parameters (e.g., cell number, 
differentiation stage, metabolic activity), but also to the limited fundamental understanding of 
the cellular and molecular processes underlying regeneration and function of specific tissues 
and organs. Indeed, to better control and standardize key output product characteristics such 
as cell identity, quality, purity and potency, the mode of action associated with tissue 
regeneration should be identified and validated. For example, in most cases it is not yet 
established whether the performance of a specific engineered product is dependent upon the 
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number of implanted cells, the cell phenotype at the time of implantation, the amount of 
specific extracellular matrix proteins deposited, or the profile of released cytokines. 
Understanding these scientific uncertainties will help to identify relevant biomarkers, 
including extracellular matrix components, proteins indicative of proliferative/differentiation 
stage and metabolites, which can serve as critical process quality control points and predict 
potency of a tissue engineered product [18]. Based on this necessary fundamental knowledge, 
the next challenge will then be to define which ranges of specific biochemical, metabolic, 
and/or environmental culture parameters (e.g., growth factors, glucose, pH, etc.) are required 
to guarantee reproducible potency features. In this regard, it is clear that the monitoring and 
control capabilities provided by bioreactor systems, linked to the scientific knowledge 
obtained through the application of defined and controlled sequences, provides a valuable 
feedback loop to refine the culture processes and optimize the properties of the engineered 
product. 
 
REGULATORY ASPECTS 
The clinical introduction of engineered tissue products will likely involve significant 
regulatory oversight, with an additional degree of complexity as compared to policies and 
guidance recently implemented on different international levels for cell therapy [19-21]. 
While manufacturing strategies based on conventional manual cell culture techniques might 
find difficulties in complying with the new regulatory framework, bioreactor-based 
manufacturing processes inherently involve automation and reproducibility that facilitates 
compliance with regulatory objectives. In particular, monitoring process parameters and 
specific properties of the developing/final graft will allow for a higher level of traceability of 
key manufacturing data related to identity, purity, and potency of the implant. Moreover, by 
minimizing the required manual procedures of handling the cells and tissue constructs by the 
operator, automated bioreactor systems with control platforms and software-based data 
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management will facilitate compliance to safety regulations. Ultimately, a stand-alone, fully-
automated and closed system would provide a GMP-compatible manufacturing unit complete 
with environment control, full operational traceability and failsafe protection measures that go 
well beyond simplistic automated cell culture.  In essence, this is in itself a kind of “GMP-in-
a-box” concept, with the potential to reduce dependence on large, costly and sometimes not 
easily available regulatory-compatible facilities (see Text Box 1). 
In order for these opportunities to be translated into effective ways to facilitate a more 
widespread use of tissue engineered products in the clinic, we foresee commonly 
underestimated difficulties and challenges, related to the practical details of implementation. 
First, the often rather undefined mode of action of engineered tissues and the limited 
availability of potency markers on a tissue level eclipses pragmatic testing protocols that can 
be realistically deployed in the production process (see section on scientific aspects). Issues 
related to the lack of certainty with which the product output provides the expected patient 
benefit challenges a credible plan for ‘validation’, namely the ability to predict performance 
with a high degree of confidence in the absence of direct data.  The validation of production 
processes is pivotal to regulatory compliance and needs considerable attention in preparation 
for regulatory review. 
The clinical deployment of bioreactors for the preparation of engineered tissues inherently 
depends upon the safe, reliable and user friendly operation of the system in production 
environments. Fundamental to any regulatory assessment is the comprehensive analysis of 
product, process, and environment risk, along with the specific implementation of risk 
mitigation practices to address ‘critical’ risks.  Risk criticality is assessed based on 
occurrence, severity and detection, with all factors playing a crucial role in identifying key 
nodes for active risk management.  As for other fields of biotechnology, the use of 
standardized and automated systems (in this case bioreactor-based manufacturing systems) 
enables critical risk factors associated with operator handling and the production process to be 
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successfully mitigated. However, an overview of risk and risk control associated with the use 
of bioreactor-systems for the production of engineered tissues, illustrated in Table 1, indicates 
the complexity and large spectrum of processes involved. Indeed, skepticism by regulatory 
authorities on the implementation of bioreactor-based graft manufacturing could be tempered 
by introducing a sound risk assessment early enough in product development.  
Beyond the characterization and mitigation of risk associated with the automated tissue 
engineering process, the regulatory approval of bioreactor systems for production of cell-
based implants for clinical use will be highly dependent upon the compliance of the 
surrounding production environment.  For facilities with pre-approval for cell manipulations, 
the integration of additional equipment to further the culturing of the implant would be 
significantly more straightforward (although appropriately challenging on the details of the 
process) than implementation in the more open environment of a specialized clinic. In this 
regard, uncertainties on the interpretation of ‘closed system’, especially considering the 
necessary sampling for off-line monitoring (e.g., for sterility tests) or the need for direct 
intervention based on “out of specification” (OOS) signals, make it difficult to identify 
precise rules on the practicality, from a regulatory/safety standpoint, of the “GMP-in-a-box” 
concept.  
 
COMMERCIAL ASPECTS 
While the promise of tissue engineering has captivated many enthusiasts and has generated 
significant international investments in research, commercially engineered products are 
confronted with tough economic realities related to uncertain cost-benefit performance and 
ultimate eligibility for reimbursement. The limited and perhaps discouraging commercial 
progress to date could be related to the fact that the basic procedures for generating 
engineered tissues have generally been based around conventional manual bench-top cell and 
tissue culture techniques. These manual techniques seem to be particularly appealing during 
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initial stages of product development (particularly for start-up initiatives) since the simple and 
wide-spread manual approach is generally viewed as being a route to minimize initial 
development time and investment costs, and allow for quick entry into clinical trials and to 
the market. However, down the line as scientific, technical and commercial momentum 
builds, production costs associated with manual production quickly become a barrier, in 
addition to the fact that the traditional techniques possess inherent risks for contamination and 
intra-/inter-operator variability.  Furthermore, pragmatic limits on the escalation of unit 
production volumes (up-scaling) and related inefficiencies in traceability result in significant 
challenges to business models that had been founded on manual protocols. As an alternative, a 
closed, standardized, and operator-independent bioreactor-based production system would 
possess great benefits in terms of safety and regulatory compliance, and despite incurring high 
product development costs initially, would have great potential to improve the cost-
effectiveness of a manufacturing process in the long run, while maximizing the potential for 
process scale-up (see Text Box 1). 
The advantages of a bioreactor-based approach appear convincing and yet bioreactor 
technology is not widely adopted.  This cannot be due to a lack of competent bioreactor 
designs, as one only needs to perform a literature or patent search to appreciate the plethora of 
various bioreactors developed to date. So why have we not seen more of a drive to implement 
bioreactors for the manufacturing of engineered products for clinical applications? 
Perhaps the clinical vision in each of the different segments of tissue engineering is still 
relatively immature and hence quality, validation and productivity demands are considered 
secondary challenges. One contributing factor to the delayed introduction of novel bioreactor 
technology could be the required change of mindset to break from well-established cell 
culture methods. To make this leap, and for bioreactors to gain greater general acceptance, 
simple and more user-friendly bioreactor systems will have to be introduced during the 
research phase, given that the routine handling of complex and technically challenging 
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systems may discourage their introduction into laboratories that lack a specialized and trained 
work force. Moreover, even if one does acknowledge that bioreactors can generate engineered 
tissues of higher quality, there is currently little data highlighting the process reproducibility 
and – to the best of our knowledge – no sound analysis that critically assesses the potential 
cost-effectiveness of a bioreactor-based production system. Indeed, economic tools to help 
guide investment decisions and to evaluate the potential cost-effectiveness of an engineered 
product are complex, rely on strong assumptions, and are not yet well-established. As a first 
step, typical methods for the analysis of factors influential in strategic planning need to be 
applied to the commercialization of bioreactor-based tissue engineering for the clinic. Without 
reference to a specific clinical indication, the results from a SWOT (Strengths, Weaknesses, 
Opportunities and Threats) analysis (see Table 2) indicate that the adoption of bioreactors in 
the clinical delivery of tissue engineering could indeed introduce attractive strengths and 
opportunities. Not surprisingly, the new bioreactor-based approach also carries certain 
weaknesses and invokes threats that need to be addressed as part of a well developed clinical, 
regulatory and reimbursement plan. In order to derive more quantitative indications, the use of 
a Headroom Method has been proposed as a simple but rigorous way to make preliminary 
conclusions as to the cost-effectiveness of a new tissue engineering treatment [22]. 
Difficulties with the implementation of such analytical tools are related to the fact that some 
critical parameters required as input, for example the expected improvement of clinical 
performance, can only be arbitrarily assumed, in lieu of the uncertainties associated with an 
undeveloped technology. 
The lack of cost-benefit analyses in the context of clinical efficacy precludes a plausible 
assessment of the likelihood of reimbursement coverage for the production and surgical 
implantation of engineered products, which in turn severely impacts the credibility of 
commercial business plans founded on the widespread use of tissue engineering. Taken 
together, challenges to the tissue engineering business model coupled with budding but as yet 
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not robust demand for bioreactor systems, it is not surprising that industry has been hesitant to 
embrace commercialization of engineered products and invest significant resources upfront to 
develop and/or utilize sophisticated manufacturing technology.  
Closer interactions between scientists/engineers and the other involved stakeholders (e.g., 
regulatory bodies, clinicians, industrial partners, health care providers) must therefore aim at 
an integrated bioreactor design, deployed in a system which can be practical and economical 
for clinical use. We now have nearly two decades of bioreactor technology for engineered 
tissues at our disposal, and although these research-oriented systems are generally too 
complex, user-unfriendly, unsafe, and expensive to be directly utilized for clinical 
applications, their underlying principles could nevertheless lay a solid foundation for more 
clinically compliant manufacturing systems. This will require the identification of only the 
most essential processes, culture parameters, and construct parameters that must be monitored 
and controlled in order to standardize production and provide meaningful quality and 
traceability data, but which minimizes risks, costs, and user-complexity.  
In this regard, it is questionable whether complex and rather costly automated/robotic 
systems, which essentially mimic established manual procedures, could actually demonstrate a 
real cost-benefit by replacing manual cell culture techniques in a manufacturing process. 
Moreover, current automation techniques may fail to capture the expert nature and role of the 
cell culture technician. Instead, bioreactor designs could be dramatically simplified, and 
related development costs significantly reduced, if we re-evaluate the conventional tissue 
engineering paradigms and implement novel concepts and techniques that could streamline 
the numerous individual bioprocessing steps. Simplified tissue engineering processes could be 
key to future manufacturing strategies by requiring only a minimal number of bioprocesses 
and unit operations, thereby facilitating simplified and compact bioreactor designs with 
limited automation requirements, with the likely result of reduced product development and 
operating costs. Here we underline the importance of simplicity and minimal costs while 
 11 
maintaining core attributes of implant consistency and overall manufacturing productivity and 
scalability. And while we have attempted to draw several parallels to bioreactors in other 
fields of biotechnology, the analogy begins to break down during up-scaling, especially in the 
context of autologous implants. Given that cells from each patient will be highly variable and 
must be processed as completely independent batches, we cannot simply upscale the total 
volume as we would a fermentation process or even for an allogeneic product. Alternatively, 
the clinical need requires “scaling out” (i.e., to replicate the same bioprocesses at multiple 
sites) simply by adding additional (low-cost) units to the production as product demand 
increases [23] (see Figure 1).  
Finally, we must ask where the potential exploitation of bioreactors lies within the broad 
spectrum of tissue engineering applications. Could there be a market for a simple and user-
friendly bioreactor for general use in basic research applications? Are hospitals a viable 
market? A closed “GMP-in-a-box” system would allow competent hospitals to manufacture 
engineered grafts on-site, without reliance upon a centralized industrial manufacturing 
facility. On the other hand, would the predominant market lie in industrial firms producing 
engineered products in-house, with the perspective of introducing automated bioreactors 
within their manufacturing process? At the present stage, none of these markets can be 
excluded, and it is likely that business models will have to be adapted to some specific upfront 
decisions. For example it is possible that a centralized manufacturing facility is appropriate 
for the engineering of allogeneic grafts, whereas hospital-based production could become a 
reality for autologous cell-based tissues.  
 
CONCLUSIONS  
The use of bioreactor-based platforms for the translation of tissue engineering strategies into 
clinical products offers attractive opportunities for exploitation, as well as the potential for 
broad implementation of cell-based grafts as therapeutic solutions. However, in order to make 
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this paradigm successful, several challenges of diverse nature need to be realistically 
considered and constructively addressed, as outlined in the roadmap proposed in Figure 2. 
The roadmap advocates that bioreactor-based manufacturing concepts need to be introduced 
in the development of a tissue engineered product as early as possible. This will allow 
academics, developers, and industry participants to (i) properly address underlying research 
questions (e.g., offering the possibility to test the effect of controlled changes in discrete 
parameters), (ii) carry out sound pre-clinical studies (e.g., offering the possibility to test the in 
vivo performance of grafts with reproducible features), and (iii) maintain strong ties with 
regulatory and commercial dimensions (e.g., offering the possibility to implement scaling 
concepts and compliance with safety requirements). The proposed roadmap also conveys that 
scientific, regulatory and commercial aspects should all be considered in each of the 
translational stages, from the initial conception to the final implementation of a clinical 
product, leading to continuous refinements and beneficial corrections.  
Last but not least, success of bioreactor-based tissue engineering products will also depend on 
the acceptance of the proposed paradigms by the involved stakeholders (e.g., surgeons, 
industry alliance partners [24], investors, health insurance companies), as well as by the 
general public (i.e., the potential patient population) [25]. In fact, while the availability of 
therapeutic products has the potential to develop the market, it should not be underestimated 
that key for their ultimate success will closely depend on the generation of a receptive society, 
which needs to be educated by appropriate dissemination activities.   
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Text box 1: Key opportunities and challenges for implementing bioreactors  
 
Scientifc aspects  
 
Key Opportunity 
Sensor-based bioreactors enable unmatched ability to regulate bioprocesses to minimize process and product 
variability. 
 
Key Challenge 
Additional scientific insight is required to maximize the utility of bioreactor technology in providing TE grafts 
with consistent properties. 
 
 
Regulatory aspects  
 
Key Opportunity 
Bioreactor-based processes, which include monitoring and data management systems, can offer a high level of 
traceability and compliance to safety guidelines. 
 
Key Challenge 
Ambiguous regulatory guidelines currently hinder the deliberate design of bioreactors which comply with 
specific and clear specifications.  
 
 
Commercial aspects 
 
Key Opportunity 
Automated bioreactor systems may enable safe and standardized production of TE grafts, maximizing the 
prospective of up-scaling and cost-effectiveness in the long-term. 
 
Key Challenge 
Models for the commercialization of TE products are not well-established, resulting in uncertainties related to 
markets, regulatory approvals, reimbursement and overall clinical adoption. 
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Table 1: Overview of Risks and Risk Mitigation for Bioreactor-based Manufacturing 
Systems.   
 
Risk Risk Control/Mitigation 
Bi
ol
og
y 
Contamination & Infection • Closed sterilized system 
• Inputs sterile/clean when introduced 
• Contamination testing on every lot (individual patient level) 
Toxicity/Bioburden/Pyrogens • Bioreactor and related fluid contacting surfaces selected from USP Grade 
• Pre-test bioreactor system with target cell type 
• Validate production bioburden and pyrogen levels 
Shear Stress Damages Cells • Bioreactor system designed with benefit of fluid modeling 
• Validate operational sequence and maximum flow rates with target cell type 
Compromised Cell Vitality & 
Performance 
• Biosensors for strict maintenance of culture conditions 
• Media and reagent sources refrigerated while on-line 
• Adaptive software to minimize effects of donor variability 
Final Cell Population Insufficient for 
Clinical Objective 
• Establish gateway specifications in multi-step bioprocesses 
• Automate monitoring of cell behavior to trigger cell collection 
Sterilization Failure • Validate according to established international standards 
Inadequate Packaging Shelf Life • Validate according to established international standards 
Bi
or
ea
ct
or
s &
 In
st
ru
m
en
ta
tio
n 
Disposable Cassette Fails to Ensure 
Consistent and Error Free Operation 
• Direct attachment of cell/tissue input container to minimize manual handling 
• Multi-layers to input container to reduce contamination risks 
• High level of operator visibility on process bioreactors for verification steps 
• Biological pathway entirely closed within cassette - zero transfer to instrument  
• Sampling ports to enable sterile withdrawal of samples (e.g. microbial testing) 
• Output container designed for direct transfer to clinical setting 
Bioreactor System Integrity Failure • Validate connections & methods 
• 100% leak test 
• Sampling program 
Sensor Reliability Issues • Sensor selection enables accurate monitoring for ex-vivo period without fouling 
• Operational back-up (i.e. dual monitoring & alternate monitoring) 
• Validate sensor tolerance to sterilization protocol 
• Validate sensor shelf life when incorporated into cassette 
Electromagnetic Interference (EMI) & 
Static Discharge Sensitivity 
• Test EMI emissions and sensitivity 
Electrical Safety Issues • Meet legislative standards for safety 
So
ft
w
ar
e 
Code Error • Design code per standards 
• Rigorous code validation practices 
Software Corruption • Standard software error checking 
• Reload from non-volatile memory 
• System watch-dog 
Power Failure Recovery • Establish redundant memory 
• Automated recovery routines 
Operating System Compromised • Code redundancy 
U
se
r 
 
Inadvertent Misuse • Design of bioreactors and instrumentation anticipate and preclude misuse 
• Failsafe operation 
• Clear instructions for use 
• Field maintenance program 
• Remote service link-up 
Inadequate Operational Records • Process tracking and storage in non-volatile memory 
• Data output via computer link 
• Compliant with regulations on electronic records 
Unauthorized Use • User security codes/redundancy 
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Text Box 2:  
SWOT Analysis for Bioreactor-based Manufacturing of Engineered Products 
Strengths Weakness 
• Bioreactors enable consistent implementation of bioprocesses 
under regulated culture conditions to maximize TE productivity 
• ‘Smart’ bioreactor systems employing integrated sensors provide 
foundation for validation of TE processes for implant production 
• Intelligent operation of system enables autonomous sequences to 
be delivered without the need for continual staff intervention 
• Bioreactor control systems utilize protective measures to ensure 
output of process is safe and effective 
• Operation of automated system and related user interface controls 
are easy to use within implant production facilities 
• Pre-configured bioreactors and related system components enable 
reduced cost of routine operation, following initial set-up 
• Automatic monitoring, collection and archiving of process data 
enhances institutional compliance with regulatory requirements 
• TE production systems based on automated bioreactor technology 
are ideally suited to progressive scale up of process throughput 
• No pre-existing market model to use as commercialization 
benchmark 
• Operational constraints associated with bioreactor design 
potentially limits visualization of on-going process  
• Automation requires upfront investment in capital equipment; 
however, follow-on costs are economical 
Opportunities Threats 
• Large regenerative medicine market [7] provides opportunity for 
TE-based product derivatives once effective implant production 
and delivery methods are available 
• The  success of a few representative models of bioreactor-based 
delivery of TE into the clinic will accelerate commercial & 
healthcare provider interest 
• Technical and administrative consistency of bioreactor-based TE 
supports transition and expansion from research through to clinic 
• Adoption of bioreactor-based standards will enhance clinical data 
analysis and reinforce regulatory documentation 
• Inherent consistency and quality of bioreactor output maximizes 
opportunity to pursue effective reimbursement for TE procedures 
• Continued refinement of scientific insights on tissue engineering 
processes can be translated to clinic via bioreactor upgrades 
• Early focus of TE in clinical therapeutics will likely focus on 
critical conditions that enable recovery of bioreactor R&D costs. 
• Cost-benefit of cell-based product may prove insufficient to 
compete with off-the-shelf alternative 
• The use of preconfigured bioreactor assemblies and automated 
techniques may require the mindset of certain users to change 
• Operation of system to produce cell-based implants via automated 
techniques potentially displaces specialized work force 
• Underlying science of bioreactor-based TE may be limited by 
insufficient supporting data (e.g. mechanism of action) 
• Innovative bioreactor technology might be constrained or delayed 
by mismatch with established regulatory standards 
• Implementation of bioreactor-based TE strategies could be 
constrained or delayed by validation challenges inherent in the 
adoption of automated processes (e.g., lack of appropriate quality 
control markers) 
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FIGURE LEGENDS 
Figure 1. Potential model for a commercial bioreactor-based system. The translation of 
bioreactor-based tissue engineering into the clinic would benefit from the integration of 
bioreactor technology into state of the art systems which meet the safety, traceability and 
efficiency expected in healthcare environments.  In order to eliminate the prospect of cross 
contamination, the bioreactor and associated media management would be ideally isolated on 
a patient-specific level through the use of disposable bioreactor ‘cartridges’ or ‘cassettes’.  
Automated operational control over the cassette would occur via a space-efficient, multi-
channel (i.e. multi-patient) instrument that operates under password-protected security access.  
Initiation and monitoring of the process underway for each patient would occur via an 
intuitive graphical interface that provides an accurate and timely indication of status 
operation, along with secure data archiving.  As the process advances within the cassette, 
biosensors associated with the bioreactors and media management system provide feedback 
on tissue culture conditions and enable the control system to maintain critical process 
parameters.  Upon completion of the process, the cassette would enable the removal of an 
output cartridge that inherently protects the internal vial during the final stages of transport to 
the surgical center for implantation. Automated cell processing systems have been developed 
by several groups such as Aastrom Biosciences Inc., (http://www.aastrom.com) and Tissue 
Genesis Inc. (http://www.tissuegenesis.com).  The example illustrated is under development 
by Octane Biotech Inc. (http://www.octaneco.com/biotech) with the essential goal of enabling 
full GMP processing on a miniature and cost-effective scale. 
Figure 2. A proposed roadmap for translating bioreactor-based engineered products 
into the clinic. Highlighted are the most critical scientific, regulatory, and commercial 
challenges that will need to be addressed along the path irrespective of the particular tissue 
engineering application. 
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Once embarking into the development of a bioreactor-based tissue engineering system, and 
targeting a specific clinical application with clear goals in terms of projected clinical outcome, 
core biological criteria associated with the engineered product, the relevant bioprocesses, and 
basic regulatory guidelines must be established and verified. Planning and conducting sound 
pre-clinical studies will allow to further assessing and validating the criteria that had been 
previously established in the core biology platform, most likely leading to refinements and 
optimization of bioprocesses as well as to a better understanding of the underlying biology. 
Interactions with industrial partners will facilitate the transition between platforms, through 
the evolution and industrialization of research based technologies as well as by defining the 
commercial potential for the product. In the final stage of the roadmap, which clearly is the 
most challenging and critical, the translation to the clinic platform will engage clinical, 
regulatory and reimbursement strategies [26]. 
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